Cytosorbents (CTSO) Free Cash Flow (2010 - 2026)

Cytosorbents (CTSO) has reported Free Cash Flow for 17 consecutive years, with -$597000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow rose 53.9% year-over-year to -$597000.0; the trailing twelve-month figure through Jun 2026 stood at -$9.3 million (up 7.39% YoY), and the FY2025 full-year result was -$12.5 million, up 14.76% from the prior year.
• Free Cash Flow grew to -$597000.0 in Q2 2026 per CTSO's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$597000.0 in Q2 2026 and bottomed at -$11.1 million in Q2 2022.
• Historically, Free Cash Flow has averaged -$4.8 million across 5 years, with a median of -$4.8 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow slumped 294.31% in 2022, then jumped 73.09% in 2025.
• Over 5 years, Free Cash Flow stood at -$5.6 million in 2022, then decreased by 17.09% to -$6.5 million in 2023, then surged by 62.94% to -$2.4 million in 2024, then plunged by 104.69% to -$4.9 million in 2025, then surged by 87.9% to -$597000.0 in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$597000.0, -$1.2 million, and -$4.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.